Clinical trials: Epirubicin
Breast Neoplasms
Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients
This is a prospective, phase IIa, multicenter, randomized, open-label study comparing a pre-surgical combination of trastuzumab and pertuzumab with concurrent weekly paclitaxel chemotherapy or endocrine therapy given for 12 weeks…
- Trial name
- TP-II (NCT03272477)
- Testing
- Perjeta Injectable Product, Herceptin, Tamoxifen
- Where
- Germany
- Volunteers
- 257 people
- Sponsor
- Palleos Healthcare GmbH
Breast Cancer
Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as epirubicin, cyclophosphamide, paclitaxel, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00433420
- Testing
- pegfilgrastim, cyclophosphamide, epirubicin hydrochloride
- Volunteers
- 2,000 people
- Sponsor
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer
Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer
This phase II trial studies how well pegylated liposomal doxorubicin hydrochloride and carboplatin followed by surgery and paclitaxel work in treating patients with stage II-III breast cancer that does not have estrogen…
- Conditions
- Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage IIA Breast Cancer
- Trial name
- NCT02315196
- Testing
- pegylated liposomal doxorubicin hydrochloride, epirubicin hydrochloride, carboplatin
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Rutgers, The State University of New Jersey
Breast Cancer
A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer
This two-arm, randomized, open-label, multicenter study will evaluate the efficacy and safety of trastuzumab emtansine in combination with pertuzumab versus trastuzumab in combination with pertuzumab and a taxane as adjuvant…
- Trial name
- NCT01966471
- Testing
- Trastuzumab Emtansine, Trastuzumab, Pertuzumab
- Where
- 295 sites in United States, Australia and 34 more
- Volunteers
- 1,846 people
- Sponsor
- Hoffmann-La Roche
Stage II-III Breast Cancer
A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer
This is a randomized, open label Phase II neoadjuvant study comparing the efficacy and safety of the combination of traditional herbal medicine for cancer immunotherapy and neoadjuvant therapy versus neoadjuvant therapy in…
- Trial name
- NCT05483439
- Testing
- cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin), anti-Her2 monoclonal antibody (Trastuzumab, Pertuzumab), traditional herbal medicine
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Shengjing Hospital
Breast Cancer, Neoadjuvant Chemotherapy
Study of Optimizing Neoadjuvant Regimens in Subtypes of Breast Cancer
There are no standard neodjuvant regimens adapted according to the different subtypes of breast cancer. This is a phase 2, randomized study to evaluate several regimens in different subtypes of breast cancer.
- Trial name
- NCT02041338
- Testing
- Paclitaxel and carboplatin, Paclitaxel, Epirubicin and Paclitaxel
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chinese Academy of Medical Sciences
Hepatocellular Carcinoma (HCC), TACE
DEB-TACE vs cTACE in HCC After TIPS
This is a Phase 3, open-label, multicenter, randomized controlled clinical trial designed to evaluate the efficacy and safety of Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE) compared with Conventional…
- Conditions
- Hepatocellular Carcinoma (HCC), TACE, TIPS, DEB-TACE
- Trial name
- UPGRADE (NCT07322848)
- Testing
- DEB-TACE, cTACE
- Where
- China
- Volunteers
- 206 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
HR+/HER2- Breast Cancer
Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)
Our center plans to conduct a randomized, open-label, parallel-controlled, multi-center phase III study to evaluate the efficacy and safety of neoadjuvant chemotherapy combined with Toripalimab for HR+/HER2- breast cancer.
- Trial name
- NCT06977893
- Testing
- Neoadjuvant Chemotherapy in Combination with Toripalimab, Neoadjuvant Chemotherapy
- Where
- 13 sites in China
- Volunteers
- 194 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Breast Cancer
Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery
RATIONALE: Huaier (Trametes robiniophila Murr) is a traditional Chinese medicine, which has been widely used in China for many years.
- Trial name
- NCT02627248
- Testing
- Huaier Granule, Epirubicin, Docetaxel
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shandong University
Breast Cancer Invasive
NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.
The goal of this clinical study is to learn if serplulimab is effective in early HR+/HER2- breast cancer. This trial serves a prospective parallel control cohort for HELEN-018 (NCT).
- Trial name
- NCT06781281
- Testing
- Serplulimab, NabPE
- Where
- China
- Volunteers
- 709 people
- Sponsor
- Henan Cancer Hospital
Breast Cancer
Cyclophosphamide, Methotrexate, and Fluorouracil, With or Without Epirubicin Hydrochloride, in Treating Women Who Have Undergone Surgery for Breast Cancer (Group III Closed to New Patients as of 12/7/2009)
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, methotrexate, fluorouracil, and epirubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT01031030
- Testing
- cyclophosphamide, epirubicin hydrochloride, fluorouracil
- Volunteers
- 800 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Breast Cancer, Chemotherapy Effect
Evaluating Xihuang Pill to Improve the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer
Evaluate the effectiveness of Xihuang Pill in improving the efficacy of neoadjuvant chemotherapy for breast cancer
- Trial name
- NCT05914753
- Testing
- Epirubicin, Cyclophosphamide, Xihuang Pill, Docetaxel, Epirubicin, Cyclophosphamide, Docetaxel
- Volunteers
- 200 people
- Sponsor
- Zhejiang Provincial People's Hospital
Breast Cancer
A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer
This open, randomized pilot feasibility trial is to evaluate the feasibility and effect of neoadjuvant everolimus plus letrozole versus neoadjuvant fluorouracil, epirubicin plus cyclophosphamide (FEC) in treating postmenopausal…
- Trial name
- NCT02742051
- Testing
- Everolimus, Letrozole, Fluorouracil
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Early-Stage Breast Carcinoma, HER-2 Positive Breast Cancer
Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer
The purpose of this trial is to evaluate efficacy and toxicity of either the combination of docetaxel, trastuzumab sc and pertuzumab (arm A) or trastuzumab emtansin (arm B).
- Trial name
- PREDIX HER2 (NCT02568839)
- Testing
- docetaxel + trastuzumab sc + pertuzumab, trastuzumab emtansin
- Where
- 7 sites in Sweden
- Volunteers
- 202 people
- Sponsor
- Thomas Hatschek
Germ Cell Tumor, Yolk Sac Tumor
Thalidomide Combined With Chemotherapy in the Treatment of Relapsed or Refractory Yolk Sac Tumor
Remarkable progress has been made in treating germ-cell tumor (GCT) through the use of platinum-based regimens. However, part of yolk sac tumor (YST) with cisplatin resistance or recurrence is nevertheless prone to relapse after…
- Trial name
- NCT06470464
- Testing
- Thalidomide combined with TGA chemotherapy (nab-paclitaxel + gemcitabine+ epirubicin)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shandong First Medical University
Malignant Neoplasm of Female Breast
Phase II Trial for Large ER-Negative Breast Cancers
A primary objective of this study is to evaluate the in vivo response of tumor to chemotherapy through gene microarray analysis.
- Trial name
- NCT01869192
- Testing
- Epirubicin, Cyclophosphamide, Docetaxel
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- University of Colorado, Denver
Breast Cancer
Randomized Phase III Trial With Docetaxel Plus Epirubicine Versus Docetaxel Plus Capecitabine for Metastatic Breast Cancer
The combination of docetaxel+epirubicin is highly effective and well tolerated as first line treatment in patients with metastatic breast cancer (MBC).
- Trial name
- NCT00429871
- Testing
- Docetaxel, Capecitabine, Epirubicin
- Where
- 10 sites in Greece
- Volunteers
- 272 people
- Sponsor
- Hellenic Oncology Research Group
Liver Cancer
Epirubicin and Thalidomide in Treating Patients With Liver Cancer
RATIONALE: Drugs used in chemotherapy such as epirubicin use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00058487
- Testing
- epirubicin hydrochloride, thalidomide
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Dana-Farber Cancer Institute
Upper Tract Urothelial Carcinoma, Bladder Recurrence
Prophylactic Intravesical Chemotherapy to Prevent Bladder Tumors After Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinomas
The purpose of this study is to evaluate the efficacy of prophylactic intravesical chemotherapy (different chemotherapy drugs and dosage regimen) in the prevention of bladder recurrence after nephroureterectomy for upper tract…
- Trial name
- NCT02547350
- Testing
- pharmorubicin or pirarubicin
- Volunteers
- 200 people
- Sponsor
- Xuesong Li
Small Cell Lung Cancer
Bevacizumab in Extensive Small Cell Lung Cancer
Despite the fact that a substantial response rate may be obtained in small-cell lung cancers (using double-drug chemotherapy: cisplatin-etoposide, PE), a cure remains an exception.
- Trial name
- CPC (NCT00930891)
- Testing
- Standard Chemotherapy (PCDE or PE), Experimental Treatment (PCDE or PE + bevacizumab), Prerandomization Chemotherapy (PCDE or PE)
- Where
- 60 sites in France
- Volunteers
- 143 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique